atropine ophthalmic low-dose myopia
Selected indexed studies
- Low-Dose 0.01% Atropine Eye Drops vs Placebo for Myopia Control: A Randomized Clinical Trial. (JAMA Ophthalmol, 2023) [PMID:37440213]
- IMI Prevention of Myopia and Its Progression. (Invest Ophthalmol Vis Sci, 2021) [PMID:33909032]
- Safety and Efficacy of Low-Dose Atropine Eyedrops for the Treatment of Myopia Progression in Chinese Children: A Randomized Clinical Trial. (JAMA Ophthalmol, 2020) [PMID:33001210]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Low-Dose 0.01% Atropine Eye Drops vs Placebo for Myopia Control: A Randomized Clinical Trial. (2023) pubmed
- IMI Prevention of Myopia and Its Progression. (2021) pubmed
- Safety and Efficacy of Low-Dose Atropine Eyedrops for the Treatment of Myopia Progression in Chinese Children: A Randomized Clinical Trial. (2020) pubmed
- Which low-dose atropine for myopia control? (2020) pubmed
- Myopia Controlling using Low Dose Atropine Eye Drop. (2024) pubmed
- Low-dose atropine 0.01% for the treatment of childhood myopia: a pan-India multicentric retrospective study. (2024) pubmed
- Myopia Control With Low-Dose Atropine Eyedrops. (2020) pubmed
- Advances in myopia prevention strategies for school-aged children: a comprehensive review. (2023) pubmed
- Effect of Low-Dose Atropine on Choroidal Thickness in Children With Myopia Progression. (2025) pubmed
- Myopia Progression Study Comparing Low-Dose (0.01%) Atropine Eye Drops with a Control Group. (2025) pubmed